Sodium-glucose cotransporter 2 (SGLT-2) inhibitors—antihyperglycemic agents, which increase urinary glucose excretion by suppressing its reabsorption in kidney proximal tubules, have proven not only to significantly reduce glycated hemoglobin (HbA1c) with low risk of hypoglycemia and weight loss promoting potential, but also to improve metabolic parameters such as blood pressure, lipid profile and uric acid levels [54]. Here, SLC5A2 is linked to Hypoglycemia.